Data Center Detected and Mitigated Emerging DDoS Attack

Micron21 Identifies and Mitigates DDoS Attack Using NSFOCUS Anti-DDoS System

SINGAPORE, Aug. 20, 2014 /PRNewswire/ — In response to the ongoing Distributed Denial of Service (DDoS) attacks plaguing enterprises and data centers worldwide, NSFOCUS announced that its Anti-DDoS System (ADS) was instrumental in assisting Australian Data Center Micron21 to detect and mitigate a sophisticated DDoS threat, named by Micron21 as a Combination Distributed Reflective Denial of Service (CDRDoS).

  • CDRDoS takes DRDoS attacks to the next level: On August 2, 2014, Micron21 detected a threat that targeted one of its customers and reached speeds of 40+gbits internationally and over 1.2gbit domestically within Australia. The company believes it represents the beginning of what is to be expected in the future of denial of service attacks. The self-named attack CDRDoS uses a combination of UDP attack vectors simultaneously, from a single attack tool. This includes NTP, DNS, SSDP and CHARGEN reflection amplification traffic that targets a single host. The company suspects the addition of SNMP will be added to further increase attack capacity in the near future.
  • Micron21 relies upon NSFOCUS ADS to implement DDoS protection service: In response to ongoing threats, Micron21 expanded its portfolio to include a DDoS Protection as a Service program in early 2013. The company provides a variety of data scrubbing options for its clients and has integrated the ADS family of products into its service model to assist them in detecting and mitigating against DDoS threats.
  • ADS mitigation appliance defends against DDoS attacks: To fight against volumetric and sophisticated attacks, NSFOCUS provides “all-in-one” (attack detection, mitigation and monitoring management) anti-DDoS solution for small to medium businesses (SMBs) and integrated protection solutions for hosting service providers, Internet data centers, such as Micron21, and large enterprises.
  • Protecting the network, from layer 3 to Layer 7: The NSFOCUS ADS protects against and mitigates network layer attacks such as SYN Flood, UDP Flood, ICMP Flood, and more importantly, application layer attacks like HTTP and DNS variants.

Terence Chong, Solutions Architect, NSFOCUS, said,

“In order to stay ahead of the ongoing threats perpetrated by aggressive hacker groups, hosting providers and Internet data centers are looking for solutions that not only protect customer data but also their own brand reputation. Micron21 is a perfect example of how data centers can supplement their offerings by incorporating a DDoS Mitigation as a Service to increase ROI and ensure customer loyalty.”

James Braunegg, Managing Director of Micron21 Datacentre, said,

“By proactively monitoring our infrastructure and customer networks, we can provide around-the-clock protection and support to adapt to threats dynamically as they occur, with real-time visibility. By integrating the NSFOCUS anti-DDoS system into our platform, our staff is able to monitor and resolve issues before they are noticed and provide the ability to react within seconds of being alerted to any threat across our network.”

About NSFOCUS

NSFOCUS is a global provider of distributed denial of service (DDoS) mitigation solutions. Founded in 2000, the company provides enterprise-level, carrier-grade solutions and services for DDoS mitigation, Web security and enterprise-level network security. With more than a decade of experience in DDoS research and development and mitigation, NSFOCUS has helped customers around the world maintain high levels of Internet security, website uptime and business operations to ensure that their online systems remain available. For more information, visit www.nsfocus.com.

TOMS Partners With Bain Capital To Accelerate Growth And Increase Scale Of One For One™ Movement

LOS ANGELES, Aug. 21, 2014  /PRNewswire/ — TOMS, the company that turned the idea of One for One™ into a global movement, today announced the signing of a definitive agreement to partner with Bain Capital, a leading global private investment firm, to accelerate the growth of the company and its giving programs around the world. TOMS Founder and Chief Shoe Giver Blake Mycoskie will continue as visionary of the company and remain the 50% owner of TOMS. Financial terms of the private transaction were not disclosed.

Founded in 2006, TOMS began as a shoe company that matched every pair of shoes purchased with a pair of new shoes given to a child in need – One for One. Since then, TOMS’ giving has grown to serve other basic needs. TOMS Eyewear gives sight to a person in need with every pair of eyewear purchased, and TOMS Roasting Co. gives one week of clean water to a person in need for every bag of coffee purchased. To date, TOMS has given over 25 million new pairs of shoes to children in need and helped restore sight to more than 250,000 people.

“This partnership will enable TOMS to grow faster and give to more people in more ways than we could otherwise,” said Mycoskie. “In eight short years, we’ve had incredible success, and now we need a strategic partner who shares our bold vision for the future and can help us realize it. We’re thrilled that Bain Capital is fully aligned with our commitment to One for One, and clearly they have the expertise to help us improve our business and further expand the scale of our mission.”

Mycoskie added, “While I believe TOMS has done a lot of good up to this point, there is so much more we can and should be doing. More importantly, I want TOMS to be relevant not only to the next generation, but the one after that, and far beyond.”

Mycoskie plans to give away at least half of his profits from the transaction by establishing a fund that identifies and supports social entrepreneurship and other causes to which he and his wife, Heather, are deeply committed.

In keeping with the One for One promise, Bain Capital has committed to give back to the community through a new charitable endeavor, funded by Mycoskie and a matching investment from Bain Capital, which will be established to support social entrepreneurs around the world.

Bain Capital has a long track record of investing in and partnering with management teams to help grow companies. Some of its consumer and retail investments have included Canada Goose, Bombardier Recreational Products, Bright Horizons, Jack Wolfskin, The Sealy Corporation, Michaels Stores, The Gymboree Corporation, Dunkin’ Brands Group, Burlington Stores and Dollarama.

“TOMS is synonymous with social responsibility and corporate impact and has demonstrated the power of being an authentic, mission-driven organization,” said Ryan Cotton, a Principal at Bain Capital. “We are extremely excited to partner with Blake Mycoskie to support the continued growth of the business and the expansion of the TOMS mission. As a firm and as individuals, we are strongly aligned with the principles of the One for One movement and its contribution to the global community.”

“Charitable involvement, social impact and global responsibility have always been important at Bain Capital,” said Josh Bekenstein, a Managing Director and a co-founder of Bain Capital. “We donate time, expertise and resources to a wide array of charitable and non-profit organizations around the world each year through partnership initiatives that make a real difference in our communities. This investment and our support of TOMS’ mission are entirely consistent with this approach.”

The Sage Group, LLC is serving as the exclusive financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal advisor to TOMS. Financo, LLC. is serving as financial advisor, Ropes & Gray LLP is acting as legal counsel, and PwC LLP is serving as accounting advisor to Bain Capital. Committed financing for the transaction is being provided by Jefferies & Company, Inc.

About TOMS:
In 2006, American traveler Blake Mycoskie befriended children in a village in Argentina and found they had no shoes to protect their feet. Wanting to help, he created TOMS, a company that would match every pair of shoes purchased with a pair of new shoes given to a child in need. One for One.® Since then, TOMS has given nearly 20 million pairs of new shoes to children in need.

Five years later, TOMS realized this movement could serve other basic needs and launched TOMS Eyewear. With every pair purchased, TOMS will help give sight to a person in need. One for One.® Since launching, TOMS has helped save or restore the sight of more than 200,000 people worldwide.

In 2014, TOMS launched TOMS Roasting Co. For each bag of coffee beans sold a person will get clean water for a week, and for every cup of coffee sold someone gets water for day.

About Bain Capital Private Equity
Bain Capital, LLC (www.baincapital.com) is one of the world’s foremost privately-held alternative investment firms, with more than $75 billion of assets under management in several pools of capital including private equity, venture capital, public equity, credit products and absolute return. Bain Capital’s more than 300 professionals are collectively the single largest investor in all of its funds and are dedicated to investing in and building its portfolio companies. Founded in 1984, Bain Capital has made private equity, growth, and venture capital investments in over 450 companies around the world, and has deep experience across five key vertical industries including consumer/retail, financial services and institutions, healthcare, industrials, and technology, media and telecommunications. Through the Bain Capital Community Partnership and Bain Capital Children’s Charity (www.baincapital.com/community), the firm and its employees serve as trusted partners with over 500 civic organizations around the world whose missions inspire them, helping to build great communities and improve the quality of life where they live and work. Bain Capital has offices in Boston, New York, Chicago, Palo Alto, London, Munich, Tokyo, Shanghai, Hong Kong, Mumbai and Sydney.

Media Contacts:

TOMS
Doug Piwinski
SVP, Marketing and Communications
310.228.8801
doug@toms.com

or

Lex Suvanto
212 729 2463
lex.suvanto@edelman.com

For Bain Capital
Alex Stanton
Stanton PR & Marketing
212-780-0701
astanton@stantonprm.com

Seiko Announces Grand Opening of First Boutique in US

– Luxury Timepiece Brand Expands Global Presence to New York City’s Madison Avenue

MAHWAH, New Jersey, Aug. 21, 2014 /PRNewswire/ — It is with great excitement that Seiko Corporation of America, a subsidiary of Seiko Watch Corporation, announces the grand opening of its first Seiko boutique to enter the United States at 510 Madison Avenue in New York City. A celebration in honor of the announcement was held at 620 Loft & Garden in New York City last night, hosted by Seiko Watch Corporation President and CEO Shinji Hattori, and attended by over 150 industry influencers including Seiko’s partner and Wimbledon champion, Novak Djokovic.

Photo – http://photos.prnewswire.com/prnh/20140820/137910

Photo – http://photos.prnewswire.com/prnh/20140820/137911

Surrounded by the world’s most iconic brands on Madison Avenue, the New York Seiko boutique is primarily dedicated to Seiko’s prestigious collections, including Astron and Grand Seiko. It also unveils collections never before sold in the US, including Galante and Credor, and various boutique exclusives within the US, including the Prospex collection. This venture continues to showcase Seiko’s progressive philosophy of presenting paramount design, quality and precision in each new project brought to the US fine timepiece market.

“The opening of the US market’s first boutique in New York City is achieving a passionate goal of mine, as I believe that the US market is the most important for Seiko outside of Japan,” says Mr. Shinji Hattori, President and CEO of Seiko Watch Corporation. “Seiko has been seeking the most ideal timing and location to spotlight our product, catering to our affordable luxury timepieces, including Grand Seiko and Astron. Opening a boutique in a market such as New York City does just that, following standards from Seiko boutiques in Paris, Amsterdam, Hong Kong and Cairo as well as the original Wako luxury specialty store opened in 1881 in Tokyo.”

The New York Seiko boutique boasts a design that expresses Seiko’s brand vision of innovation and refinement as well as its core value of being the only watch manufacturer with every watchmaking expertise. Seiko’s brand elements of history, technology, luxury and craftsmanship are found throughout the boutique, focusing on a modern yet sophisticated style.

For more information on the New York Seiko boutique, visit www.seikousa.com/boutique.

For more information on Seiko Corporation of America, visit www.seikousa.com.

For more information on Seiko Watch Corporation, visit www.seikowatches.com.

CoinTerra™ breaks $1 GH/s barrier with next-generation Bitcoin mining contracts

AUSTIN, Texas, Aug. 21, 2014 /PRNewswire/ — CoinTerra, the market leader in Bitcoin mining solutions today announced mining contracts with pre-order prices as low as $0.99 per GH/s for 12-month hosted full service Bitcoin mining contracts through CoinTerra Mining.

Logo – http://photos.prnewswire.com/prnh/20140128/MM54190-c

After becoming the first Bitcoin mining company to offer 1 PH/s investment grade mining contracts with immediate availability, CoinTerra now opens pre-orders for mining contracts priced as low as $0.99 per GH/s with a December 29th start date.

This extremely competitive pricing is made possible through the expected introduction of CoinTerra’s next generation Bitcoin mining hardware: the AIREMiner™ which will utilize CoinTerra’s highly scalable TruePeta™ architecture for high performance enterprise level Bitcoin mining.

The TruePeta architecture was developed around the proven TerraMiner™ IV hardware platform and will through the introduction of the AIREMiner™ see massive gains in hashing performance as well as power efficiency.

“With the AIREMiner product launch only months away, CoinTerra is now in the unique position of being able to open pre-orders for fully-hosted Bitcoin mining contracts at an unbeatable price-per-gigahash.” said Ravi Iyengar, CEO – CoinTerra, Inc.

CoinTerra’s new pre-order Bitcoin mining contracts offer a range of performance plans, ranging from 12-month, 2 TH/s mining contract priced at $3,500 up to a 1 PH/s, 12-month contract for $990,000 — an amazing $0.99 per GH/s for a fully-hosted investment grade Bitcoin mining contract.

Mining contract customers are able to combine multiple contracts to create a personalized hash power plan. After the mining contract is activated, customers receive weekly payouts to their Bitcoin wallet address, based on the hash power of the customers’ mining contract(s).

“When we were developing the TerraMiner IV last year $3/GH was our target for standalone hardware. Now, just one year later we are able to offer fully hosted mining contracts at a fraction of that price.” said Dr. Timo Hanke, CTO – CoinTerra, Inc.

To pre-order a CoinTerra Mining bitcoin mining contract with a December 29th start date, visit: https://mining.cointerra.com/shop

Visit CoinTerra on the web: https://cointerra.com
Follow CoinTerra on Twitter: https://twitter.com/cointerra

General inquiries please contact:
+1-512-270-6050
info@cointerra.com

About CoinTerra

Founded in Austin, Texas in mid-2013, CoinTerra is currently one of the fastest-growing technology startups in the world. CoinTerra designs, produces, and operates systems that power the Bitcoin blockchain network.

CoinTerra’s state-of-the-art design methodologies and advanced architectures enable the delivery of enterprise level Bitcoin mining solutions with the highest performance and lowest total cost of ownership available on the market today.

CoinTerra boasts a highly experienced engineering team of semiconductor architects and designers who have previously designed some of the world’s highest performance CPUs, GPUs, SOCs and chipsets for Apple®, Intel®, Nvidia®, Qualcomm® and Samsung®.

CoinTerra, the CoinTerra logo, TerraMiner, TruePeta, AIREMiner and Shiva are trademarks of CoinTerra, Inc. in the U.S. and other countries. Other trademarks belong to their respective owners. Features, pricing, availability and specifications are subject to change without notice.

Synthetic drugs a major drag on development and the rule of law in East and Southeast Asia

20 August 2014 – East and Southeast Asia remain the world’s largest markets for synthetic drugs, and the methamphetamine problem is showing signs of accelerating, according to senior policy, law enforcement and justice delegates at a special regional conference organized by UNODC’s Global SMART Programme which started today in Yangon, Myanmar.

Growing demand in East and Southeast Asia for methamphetamine is being met by large-scale production in China, Myanmar and several other countries in the region. Information presented at the conference confirms continued high, and rising, demand and supply of methamphetamine.

“Organized crime groups are well positioned to take advantage of regional integration agreements to expand the trafficking of synthetic drugs and precursor chemicals” said Jeremy Douglas, UNODC Regional Representative for Southeast Asia and the Pacific. “Capacities to ensure the rule of law vary greatly across the region, and this evolving and growing threat diverts increasing amounts of scarce state resources away from efforts to develop and improve governance. It can’t be ignored that the billions generated for organized crime exceed the size of several national economies in the region. Where is the money going?” added Mr. Douglas. 

While most of the methamphetamine produced in East and Southeast Asia is consumed within the region, large quantities are also being trafficked to nearby major markets such as Japan, Australia and New Zealand, and more recently to neighbouring South Asia. Transnational criminal groups also continue to identify new precursor sources and methods for production, and are diversifying trafficking routes.

Myanmar remains a major source of both methamphetamine pills and crystal methamphetamine, or “ice”, with significant volumes from the country being seized in neighbouring states. At the same time officials from the Government of Myanmar acknowledged that methamphetamine use is rapidly increasing across the country.

“A much greater degree of information sharing and cooperation is needed to effectively respond to the synthetic drug and precursor problems in our country and across ASEAN” said Pol. Brig. Gen. Kyaw Win of the Central Committee for Drug Abuse Control (CCDAC), Ministry of Home Affairs. “No country can tackle these challenges alone, and there is no doubt we need improved training and support for frontline law enforcement and justice officers, especially along the Mekong corridor and in remote areas of the region.”

Several delegations raised concerns about new psychoactive substances (NPS), also known as “legal highs”, being produced by introducing slight modifications to the chemistry of controlled drugs. The fast-paced nature and evolution of the regional drug market has raised concerns that transnational organized criminal groups are expanding product lines to target young people.

Background – the Global SMART Programme

UNODC launched the Global SMART Programme in 2008 to enhance the capacity of states and authorities in East and Southeast Asia to generate, manage, analyse, report and use synthetic drug and precursor information, and to apply this evidence-based knowledge to strategy, policy and programme design and implementation. Eleven countries in the region receive related assistance from UNODC through Global SMART – Brunei Darussalam, Cambodia, China, Indonesia, the Lao People’s Democratic Republic, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Viet Nam.

The Global SMART Programme receives financial support from the Governments of Australia, Canada, Japan, New Zealand, the Republic of Korea, Russian Federation, Thailand, the United Kingdom and the United States.

Related information:

UNODC Regional Office for Southeast Asia and the Pacific

Amerigen Pharmaceuticals Ltd. Announces that its Chinese Subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has Received Chinese FDA (CFDA) Approval and has Subsequently Launched its Generic Mecobalamin 0.5 mg Tablets into the China Domestic Market

LYNDHURST, N.J., Aug. 20, 2014 /PRNewswire/ — Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic market. Under the terms of a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is manufacturing the product at its US FDA approved and China CFDA certified oral solid dose facility in Suzhou, China. Sinochem is distributing the product under the Suzhou Amerigen label with exclusive sales rights in the People’s Republic of China.

John Lowry, Amerigen’s President & CEO, commented, “The approval and launch of Mecobalamin is Amerigen’s first generic product entry in China and we are very pleased to have Sinochem, a leading and highly reputable player in the Chinese pharmaceutical industry, participate in this important milestone as our sales and distribution partner. We expect additional near term product approvals in China as we continue to bring high quality, locally manufactured generic products to the rapidly growing Chinese market.”

Mr. Ziqiang Wu, General Manager of Sinochem Pharma, stated, “Sinochem is pleased to see that the Mecobalamin Tablet product produced by Suzhou Amerigen Pharmaceuticals Co. Ltd. has been approved by CFDA, which embodies a solid step towards the business cooperation on generic drugs in the Chinese market. We also expect to deepen the cooperation with Amerigen and expand more high-quality drugs into this fast-growing drug market.”

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group’s Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA’s with the US FDA and the Chinese CFDA. Amerigen’s focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen’s products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.